PPCB — what changed in the latest 10-K
A section-by-section comparison of PPCB's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-K · 2026-09-25 vs the prior 10-K · 2025-09-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| Business | Text added/removed | +32 | −21 | ~50 | 142 |
| Risk factors | No paragraph-level changes | 0 | 0 | 0 | 8 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 1 |
| MD&A | Text added/removed | +27 | −19 | ~12 | 21 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 7A)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
Business
Text added vs the prior filing · source: 10-K · 2026-09-25
In 2022, ovarian cancer was the eighth most diagnosed cancer among women in the world and accounts for an estimated 324,603 new cases and 206,956 deaths worldwide (World Cancer Research Fund International). In the United States, 21,010 new cases and 12,450 related deaths are estimated to occur in 20…
A third collaborative, two-year research project commenced in March of 2026, with the universities of Jaén and Granada undertaking the evaluation of a senescence-modulating compound to mitigate gemcitabine-induced normal cell senescence in pancreatic cancer models. The project will specifically eval…
M50096571 Canada 2814958 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent Granted
M50177545 China ZL201710885368.4 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen Granted
M50206824 Australia 2016353539 Proenzyme composition Granted
Text removed vs the prior filing · source: 10-K · 2025-09-29
In 2020, ovarian cancer is the eighth most diagnosed cancer among women in the world and accounts for an estimated 313,959 new cases and 207,252 deaths worldwide (World Cancer Research Fund International)., In the USA, 19,880 new cases (2015 – 2019) and 12,810 related deaths (2016 – 2020) are estima…
M50177545 China ZL201710885368.4 A pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen Granted 2009905147
M50096571 Canada 2814958 A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent Granted 2009905147
M53188747 United States of America 17/862120 Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent Abandoned by client (D) 2009905147
M50206973 United States of America 15/775375 Proenzyme composition Application allowed 2015904678
MD&A
Text added vs the prior filing · source: 10-K · 2026-09-25
Administration expense increased to $670,607 for the year ended June 30, 2026 as compared to $108,950 for the year ended June 30, 2025. This increase of approximately $562,000 is primarily attributable to the increase in public company expenses of approximately $113,000, business franchise tax of ap…
Compensation and related taxes increased to $2,275,937 for the year ended June 30, 2026 as compared to $23,296,390 for the year ended June 30, 2025. This decrease of approximately $21,020,000 is primarily attributable to the decrease in stock-based compensation expenses of approximately $21,260,000 …
Professional and consulting expenses decreased to $14,572,616 for the year ended June 30, 2026 as compared to $33,623,000 for the year ended June 30, 2025. This decrease of approximately $19,050,000 is primarily attributable to the decrease in stock-based consulting and stock-based legal services of…
Occupancy expenses increased to $40,932 for the year ended June 30, 2026 as compared to $26,560 for the year ended June 30, 2025. This increase in both periods are primarily attributable to the increase of monthly rental fees as a result of the lease renewal with the related party lessor in May 2025…
Research and development expenses increased to $625,477 for the year ended June 30, 2026 as compared to $223,721 for the year ended June 30, 2025, an increase in research and development expenses of approximately $402,000.
Text removed vs the prior filing · source: 10-K · 2025-09-29
Administration expenses increased to $57,027,850 for the year ended June 30, 2025, as compared to $1,253,797 for the year ended June 30, 2024. This increase of approximately $55,774,000 is primarily attributable to the increase in stock-based compensation expenses of approximately $37,800,000 to our…
Occupancy expenses decreased to $26,560 for the year ended June 30, 2025, as compared to $34,150 for the year ended June 30, 2024. This decrease of approximately $8,000 is primarily attributable to exchange rate movements over the period when compared to the same period in 2024.
Research and development expenses decreased to $223,721 for the year ended June 30, 2025 as compared to $248,102 for the year ended June 30, 2024, a decrease in research and development expenses of approximately $24,000.
Such research and development expenses are related to the two-year collaboration agreement with University of Jaén, which was executed in October 2020 to provide certain research services to the Company ending on October 2022, relating to the investigation of a fully synthetic recombinant version of…
Interest expense decreased to $563,757 for the year ended June 30, 2025, as compared to $665,841 for the year ended June 30, 2024. Interest expense is primarily comprised of approximately $304,000 of debt discount amortization and $255,000 of interest expense from accrual of interest expense and oth…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice